For instance, mAbs targeting cytokines such as TNF-α, IL-17, or IL-23 have significantly improved the management of autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD).2 Small molecule inhibitors have also shown efficacy in many conditions. This evidence concerns the gene IL17A and inflammatory bowel disease.